NEWS
October 20, 2009
Synageva BioPharma Announces Completion of $45 Million Financing with New $12 Million Investment, Addition of New Leaf Venture Partners to Investment Group, and Expansion of Senior Leadership Team
July 1, 2009
Morphotek®, Inc. Announces a Research Collaboration Agreement with Synageva BioPharma to Develop Potential Treatments for Cancer and Infectious Disease
May 5, 2009
Synageva Biopharma Adds Two New Investors and Announces Additional Funding
April 15, 2009
Synageva Biopharma Announces $30 Million Equity Financing
UPCOMING EVENTS
J.P. Morgan - 28th Annual Healthcare Conference
January 11-14, 2010
San Francisco, CA
BioPartnering North America
January 24-26, 2010
Vancouver, BC, Canada
LDN World Symposium 2010
February 10-12, 2010
Miami, FL
BioNetwork East
March 15-17, 2010
Miami, FL
|
Synageva is a biopharmaceutical company dedicated to discovering, developing, and commercializing medicines for patients with rare diseases and high unmet medical need. Our guiding philosophy is that every patient fundamentally deserves to have effective treatment options for their disease, regardless of how rare their condition may be.
Synageva has assembled a team with a unique depth, breadth, and proven track record of successfully bringing therapies to market for rare and ultra rare diseases. Every individual at Synageva shares an enduring commitment to apply the most advanced protein technologies, including our proprietary SEP™ protein platform, to build a sustainable pipeline of therapies that helps improve the lives of patients with a variety of rare disorders.
|
